Hodgkin's disease and birth outcome: a Danish nationwide cohort study by Langagergaard, V et al.
Hodgkin’s disease and birth outcome: a Danish nationwide cohort
study
V Langagergaard*,1,2, E Horvath-Puho
1, M Nørgaard
1, B Nørga ˚rd
1 and HT Sørensen
1
1Department of Clinical Epidemiology, Aarhus University Hospital, Ole Worms Alle ´ 150, Aarhus C DK-8000, Denmark;
2Department of Epidemiology,
Institute of Public Health, Aarhus University, Vennelyst Boulevard 6, Aarhus C DK-8000, Denmark
In a Danish nationwide cohort study of 292 births from 1973 to 2002 in women with Hodgkin’s disease (HD), we compared birth
outcome with 14042 births from a cohort of mothers without cancer. We found no substantially increased risk of preterm birth, low
birth weight at term, or stillbirth and no difference in proportion of male newborns for 192 children of women with HD before
pregnancy. The prevalence odds ratio (POR) for congenital abnormalities was 1.7 (95% confidence interval (CI): 0.9–3.1). Among 15
newborns of mothers diagnosed during pregnancy, the POR of preterm birth was 26.6 (95% CI: 8.5–83.0), but five out of the eight
preterm deliveries among these women were elective. We found no substantially increased risk of adverse birth outcome among
85 newborns of women diagnosed within 2 years postpartum, though effect estimates were imprecise. The overall findings are
reassuring, they cannot exclude the possibility of an increased risk of congenital abnormalities for newborns of women diagnosed with
HD before pregnancy.
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Hodgkin’s disease (HD) can affect women of childbearing age
(Fisher and Hancock, 1996). Advances in its treatment have led to
an overall 5-year relative survival of more than 80% (Melbye and
Adami, 2002). However, there is concern (Swerdlow et al, 1996)
that treatment may affect future pregnancies either by direct
effects on the reproductive tract or by causing mutations in germ
cells (Nagarajan and Robison, 2005). Furthermore, cancer treatment
administered in the first trimester may be teratogenic (Fisher and
Hancock, 1996), while detriments in maternal well-being may influence
pregnancies in women with preclinical HD (Koren et al, 1996).
Nevertheless, data concerning birth outcome in women with
previous HD are sparse and consist mainly of case series (McKeen
et al, 1979; Andrieu and Ochoa-Molina, 1983; Green and Hall,
1988; Aisner et al, 1993; Brierley et al, 1998). A few of these case
series, which included birth outcome in 15–54 women found a
high prevalence of adverse outcome. Green and Hall (1988)
reported 4 stillbirths among 28 pregnancies (14.3%) in women
with previous HD, while McKeen et al (1979) reported 6
premature/low birth weight children (15.0%) and 3 with major
congenital abnormalities (7.5%) among 40 pregnancies. The
remaining studies found little, if any, detrimental effect on birth
outcome among women capable of becoming pregnant (Andrieu
and Ochoa-Molina, 1983; Aisner et al, 1993; Brierley et al, 1998).
Likewise, a few case series found normal birth outcome in women
diagnosed with HD during or shortly after pregnancy (Woo et al,
1992; Anselmo et al, 1999; Aviles and Neri, 2001).
We examined the risk of adverse birth outcomes in a Danish
nationwide cohort of women with HD before or during pregnancy,
or within 2 years after delivery and compared them with those in a
cohort of pregnant women without cancer.
MATERIALS AND METHODS
We used the Danish Cancer Registry, which has covered all
incident cancers in Denmark since 1943, classified according to the
International Classification of Diseases (ICD-7) (Storm et al, 1997),
to trace all women with a diagnosis of HD (ICD-7 code 201).
Information included the civil registration number of the woman,
date of diagnosis, and radiation treatment administered within 4
months of diagnosis.
Since 1 January 1973, all births in Denmark have been registered
in the Danish Medical Birth Registry (Knudsen and Olsen, 1998).
Data are obtained from birth notifications, which are completed by
midwives (who attend all births, including home births, in
Denmark). The main variables in the Birth Registry are gestational
age, birth weight, parity, stillbirth, place of birth, and the civil
registration number of the mother and child (which encodes sex
and date of birth and is assigned to all live-born children and new
residents; Frank, 2000).
Using the civil registration number, we linked the Cancer
Registry data with the Birth Registry to establish a cohort of all
Danish women with a diagnosis of HD in, 1970–2002, and who
gave birth in 1973–2002. Women were included if they were
diagnosed with HD before pregnancy, during the pregnancy, or
until 2 years postpartum. We restricted all analyses to singleton
births, since multiple births have been associated with an adverse
birth outcome (Pinborg et al, 2004).
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matched by month and year of the birth, by county of mother’s
residence, and born to 50 different women who were not diagnosed
with any cancer before, during, or within 2 years after the
pregnancy were selected from the Birth Registry. If fewer than 50
births fulfilled the matching criteria, we used all the available
births. If more than 50 comparison births were eligible after
matching, we selected a random subset of 50 births. On average, 48
comparison births were selected for each exposed birth.
The outcome data collected from the Birth Registry included
preterm birth (birth before 37 completed weeks of pregnancy),
low birth weight at term o2500g with X37 completed weeks),
stillbirth (delivery of a dead foetus at X28 completed weeks of
pregnancy), male proportion of newborns, and birth weight. The
potential confounders included maternal age, parity, gestational
age, and calendar period of the birth. For live-born children, data
on congenital (including chromosomal) abnormalities, diagnosed
during the first year of life were collected from the National
Hospital Discharge Registry, covering all hospital discharge
diagnoses since 1977 and outpatient visits since 1995 (Andersen
et al, 1999). Thus, data on congenital abnormalities applied to
births from 1977 to 2002. The data include the civil registration
number, dates of admission and discharge, and up to 20 discharge
diagnoses, (ICD-8 before 1994 and ICD-10 from 1994 onwards;
Andersen et al, 1999). The codes for congenital (including
chromosomal) abnormalities were 740.00–759.99 in ICD-8 and
Q0.00 to Q99.9 in ICD-10. Diagnoses of congenital dislocation of
the hip and undescended testis were excluded because of their
poor validity (Larsen et al, 2003).
Birth weights X7000g probably reflected coding errors and
were excluded, as were births with a gestational age below 20 or
over 44 weeks. Owing to a coding change in the Birth Registry in
1978, there were more missing data on gestational age for the years
1978–1981 than for other years (mean 22.6% missing for 1978–1981,
compared with 0.8% in 1973–1977 and 1.2% in 1982–2002). Births
without data on gestational age were excluded from the study
(N¼20 in the exposed and 698 in the comparison cohort).
We classified the births of women with HD into three groups:
group 1 included the first birth after an HD diagnosis (that is,
women who were diagnosed before pregnancy). Group 2 included
the births by women diagnosed with HD during pregnancy (that is,
diagnosed between the first day in the last menstruation until the
date of birth). Group 3 included births by women who were
diagnosed with HD after delivery (that is, diagnosed between the
day after the delivery until 2 years later). If a woman gave birth
more than once in this 2-year period, only the last birth before
the HD diagnosis was included based on the assumption that the
preclinical cancer would be more likely to affect the birth closest to
the time of diagnosis.
For all three groups, we computed the difference between
proportions of male newborns of mothers with HD and
comparison mothers.
Table 1 Characteristics of births by women with Hodgkin’s disease and by women in the comparison cohort
Group 1 Group 2 Group 3
Women with
Hodgkin’s
(N¼192)
Comparison
cohort
(N¼9247)
Women with
Hodgkin’s
(N¼15)
Comparison
cohort (N¼706)
Women with
Hodgkin’s
(N¼85)
Comparison
cohort
(N¼4089)
Maternal age at delivery, number (%)
o25 years 27 (14.1) 1916 (20.7) 5 (33.3) 176 (24.9) 19 (22.4) 937 (22.9)
25–29 years 74 (38.5) 3528 (38.2) 7 (46.7) 284 (40.2) 36 (42.4) 1627 (39.8)
30–34 years 69 (35.9) 2628 (28.4) 2 (13.3) 175 (24.8) 22 (25.9) 1101 (26.9)
X35 years 22 (11.5) 1175 (12.7) 1 (6.7) 71 (10.1) 8 (9.4) 424 (10.4)
Age at delivery (years)
Mean (±s.d.) 29.0 (±4.4) 28.6 (±4.9) 26.5 (±4.4) 28.0 (±5.0) 28.0 (±4.9) 28.2 (±4.8)
Minimum/maximum 16–38 15–47 20–36 16–45 18–41 16–46
Parity, number (%)
1 135 (70.3) 4204 (45.5) 10 (66.7) 346 (49.1) 42 (49.4) 1848 (45.2)
X2 57 (29.7) 5031 (54.5) 5 (33.3) 358 (50.9) 43 (50.6) 2238 (54.8)
Data missing 0 (0.0) 12 (0.1) 0 (0.0) 2 (0.3) 0 (0.0) 3 (o0.1)
Calendar period of birth, number (%)
1973–1986 59 (30.7) 2771 (30.0) 7 (46.7) 319 (45.2) 31 (36.5) 1472 (36.0)
1987–1994 52 (27.1) 2540 (27.4) 3 (20.0) 144 (20.4) 30 (35.3) 1458 (35.7)
1995–2002 81 (42.2) 3936 (42.6) 5 (33.3) 243 (34.4) 24 (28.2) 1159 (28.3)
Offspring (sex), number (%)
Male 96 (50.0) 4735 (51.3) 11 (73.3) 353 (50.1) 52 (61.2) 2101 (51.4)
Female 96 (50.0) 4500 (48.7) 4 (26.7) 351 (49.9) 33 (38.8) 1985 (48.6)
Data missing
a 0 (0.0) 12 (0.1) 0 (0.0) 2 (0.3) 0 (0.0) 3 (o0.1)
Gestational age (weeks)
b
Mean (±s.d.) 39.5 (±2.1) 39.5 (±1.9) 37.0 (±3.4) 39.6 (±1.7) 39.5 (±1.8) 39.6 (±1.8)
Minimum/maximum 26–42 23–44 33–42 23–44 31–43 25–44
Birth weight (g)
b
Mean (±s.d.) 3462 (±581) 3464 (±571) 2938 (±649) 3450 (±539) 3412 (±576) 3460 (±556)
Minimum/maximum 803–5000 655–5600 1690–4400 570–5200 1870–4720 820–5530
Abbreviation: CPR-number¼civil registration number. Group 1: births by women diagnosed with Hodgkin’s disease before pregnancy. Group 2: births by women diagnosed
with Hodgkin’s disease during pregnancy. Group 3: births by women diagnosed with Hodgkin’s disease within 2 years after giving birth.
aBirths with missing data on sex were all
stillbirths who had no CPR-number.
bStillborn babies were excluded from the analyses of mean gestational age and mean birth weight.
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relative risks with associated 95% confidence intervals (95% CIs)
for preterm birth, low birth weight at term, stillbirth, and
congenital abnormalities. The PORs were controlled for month
and year of birth and county of mother’s residence by matching.
We used unconditional logistic regression analysis to further
adjust for maternal age and parity. We also included the calendar
period of the birth (1973–1986, 1987–1994, and 1995–2002), as an
independent variable in the model. Although there was no change
in the risk estimates when calendar period of birth was included in
the model, we kept the variable in the model. Stillborn children
were excluded from the analyses of preterm birth, low birth weight
at term, and congenital abnormalities.
To examine whether sex of the child or maternal radiotherapy
modified the POR estimates for births in group 1, we repeated the
analyses in strata of boys and girls and strata of births of women who
were treated with radiotherapy and women who were not.
Furthermore, to examine whether calendar period of HD diagnosis
modified the POR estimates for births in group 1, we repeated the
analyses in different calendar periods of HD diagnosis (1981–1990
and 1991–2000), using 1970–1980 as reference. We used the Wald
test to evaluate the homogeneity of the POR estimates for congenital
abnormalities in 1981–1990 and 1991–2000. The low count of
outcome events in groups 2 and 3 precluded stratified analyses.
We used linear regression to estimate differences in mean birth
weight, while controlling for maternal age, parity, gestational age,
and calendar period of birth. Stillborn children were excluded
from these analyses.
The study was approved by the Danish Data Protection Agency
(record no. 2003-41-2833). All analyses used SAS software, version
8.2. The SAS procedures used were PROC FREQ, PROC MEANS,
PROC LOGISTIC, and PROC GLM.
RESULTS
In total, we identified 292 singleton births delivered by women
with HD and selected 14042 singleton births for the comparison
cohort. The characteristics of births in the three groups and their
comparison births are shown in Table 1. Of the 292 births by
women with HD, 192 occurred in group 1. The median number of
days from the time of diagnosis until pregnancy (that is, the first
day in the last menstruation) was 1824 days (range: 279–7877
days). The majority of women (76%) in group 1 were X20 years of
age at time of HD diagnosis (data not shown) and the mean age at
delivery was 29.0 years. Seventy percent of the women gave birth
for the first time. Group 2 included 15 births (eight women were
diagnosed in the second trimester and seven in the third). In this
group, the mean age at delivery was 26.5 years and 66.7% gave
birth for the first time. Group 3 included 85 births. The median
number of days from date of giving birth until date of cancer
diagnosis was 321 days (range: 6–709 days). The mean age at
delivery was 28.0 years, and 49.4% of the women gave birth for the
first time.
The prevalence of male newborns of women with HD in group 1
was 50.0%, compared with 51.3% among the matched comparison
mothers (difference¼ 1.3%, 95% CI:  8.4 to 5.8). The corres-
ponding findings were 73.3 vs 50.1% (difference¼23.2%, 95% CI:
5.1–45.6) for group 2, and 61.2 vs 51.4% (difference¼9.8%, 95%
CI:  0.7 to 20.3) for group 3.
Table 2 shows PORs for preterm birth, low birth weight at term,
stillbirth, and congenital abnormalities for newborns in all three
groups. For group 1, there was no increased risk of preterm birth
or low birth weight at term. We found only 1 stillbirth among 192
births, corresponding to a POR of 2.0 (95% CI: 0.3–15.4). The POR
for congenital abnormalities was 1.7 (95% CI: 0.9–3.1). In groups 2
and 3, there were no children with low birth weight at term and no
stillbirths. The POR of preterm birth in group 2 was 26.6 (95% CI:
8.5–83.0). However, five of the eight preterm deliveries among
women with HD were elective preterm deliveries. There was 1 child
with a congenital abnormality among 13 births in group 2
(POR¼2.7, 95% CI: 0.3–22.8) and 4 children with congenital
abnormalities among 78 births in group 3 (POR¼1.6, 95% CI:
0.6–4.5). The specific types of congenital abnormalities identified
in children of women with HD in groups 1, 2, and 3 are listed
according to affected organ system in Table 3.
Table 4 shows the birth outcomes in group 1, stratified
according to maternal radiotherapy (yes/no) and three calendar
periods of HD diagnosis. Stratification suggested a slightly lower
risk (except for stillbirths) of adverse birth outcomes in women
Table 2 Prevalence odds ratios of birth outcome in women with Hodgkin’s disease
Hodgkin’s disease cohort, Comparison cohort, Prevalence odds ratio
a Prevalence odds ratio
b
outcome/total (%) outcome/total (%) (95% CI) (95% CI)
Births in group 1 (N¼192) (N¼9247)
Preterm birth 12/191 (6.3) 479/9162 (5.2) 1.2 (0.7–2.2) 1.1 (0.6–2.0)
Low birth weight at term
c 2/177 (1.1) 145/8649 (1.7) 0.7 (0.2–2.7) 0.6 (0.2–2.6)
Stillbirth
d 1/192 (0.5) 35/9247 (0.4) 1.4 (0.2–10.1) 2.0 (0.3–15.4)
Abnormalities
e 11/181 (6.1) 323/8673 (3.7) 1.7 (0.9–3.1) 1.7 (0.9–3.1)
Births in group 2 (N¼15) (N¼706)
Preterm birth 8/15 (53.3) 30/704 (4.3) 25.7 (8.7–75.4) 26.6 (8.5–83.0)
Low birth weight at term
c 0/7 (0.0) 9/674 (1.3) — —
Stillbirth
d 0/15 (0.0) 2/706 (0.3) — —
Abnormalities
e 1/13 (7.7) 18/606 (3.0) 2.7 (0.3–22.1) 2.7 (0.3–22.8)
Births in group 3 (N¼85) (N¼4089)
Preterm birth 5/85 (5.9) 205/4080 (5.0) 1.2 (0.5–2.9) 1.2 (0.5–2.9)
Low birth weight at term
c 0/80 (0.0) 48/3866 (1.2) — —
Stillbirth
d 0/85 (0.0) 9/4089 (0.2) — —
Abnormalities
e 4/78 (5.1) 124/3742 (3.3) 1.6 (0.6–4.4) 1.6 (0.6–4.5)
Abbreviation: CI¼confidence interval. Group 1: birth outcome in women diagnosed with Hodgkin’s disease before pregnancy. Group 2: birth outcome in women diagnosed
with Hodgkin’s disease during pregnancy. Group 3: birth outcome in women diagnosed with Hodgkin’s disease within 2 years postpartum.
aControlled for month and year of the
birth and maternal county of residence (by matching).
bFurther adjusted for maternal age (o25, 25–29, 30–34, and X35 years) and parity (1 and 2+) by logistic regression.
Calendar period of the birth (1973–1986, 1987–1994, and 1995–2002) was also included as an independent variable in the model.
cPreterm births were excluded from the
analyses of low birth weight at term.
dStillborn babies were excluded from the analyses of preterm birth, low birth weight at term, and congenital abnormalities.
eData on
congenital abnormalities included births from 1977 to 2002.
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POR for congenital abnormalities increased with calendar time of
HD diagnosis (Wald test of the homogeneity of the POR estimates
for 1981–1990 and 1991–2000, with 1970–1980 as reference;
P¼0.25). Stratification according to sex of newborns did not
substantially change the estimates (data not shown).
The multiple linear regression analyses showed that newborns in
all three groups had nearly the same mean birth weight as
newborns in the comparison cohort (data not shown).
DISCUSSION
This nationwide cohort study on the relation between maternal HD
and adverse birth outcome did not show any increased risk of
preterm birth or low birth weight at term, and no substantial
increased risk of stillbirth in women with previous HD. However,
we cannot rule out the possibility of a higher risk of congenital
abnormalities for newborns of these women.
The accuracy of our risk estimates depends on several factors.
The main strength of the study is the underlying uniform health-
care system, with complete registration of cancers and births and
complete follow-up on congenital abnormalities diagnosed during
the first year of life, allowing for a population-based design.
Information on congenital abnormalities in the Hospital Discharge
Registry is generally of high quality, with an 85% correct coding
rate (Larsen et al, 2003). The quality of most outcome variables in
the Birth Registry is high, but gestational age is subject to some
misclassification (Kristensen et al, 1996) but is probably non-
differential between HD and cancer-free mothers.
Although our study population was large compared with other
studies, a limitation is the small number of outcomes. Furthermore,
the data lacked clinical detail on radiation fields, doses, and duration
of treatment, and we had no information on chemotherapy or disease
stage; radiotherapy details (yes/no) from the Cancer Registry may be
inaccurate, because they are not routinely validated. However, a study
of childhood cancer survivors reported that 97 out of 110 patients
treated with radiotherapy (88%), and 78 out of 79 patients not
treated with radiotherapy (99%) were correctly coded in the
Registry (Ross et al, 2003).
Women with early-stage HD, which is often located above the
diaphragm, were probably more likely than women with more
advanced stages, to receive radiotherapy, since the typical
treatment of early-stage disease in our study period has been
either radiation alone (with minimal effect on the gonads in
case of supradiaphragmatic location), or a few series of com-
bination chemotherapy followed by radiation. In contrast, later
stages of HD have typically been treated with six series of
combination chemotherapy and only rarely radiotherapy. Thus, an
uneven distribution of stage could have biased our results and may
explain our finding of a lower risk of adverse birth outcomes
for women treated with radiotherapy, compared with those who
were not.
Fetal abnormalities may lead both to miscarriage (Yusuf and
Naeem, 2004) and to induced abortion, but we had no data on
these outcomes. Thus, selection bias could have occurred if women
with HD had more miscarriages and induced abortions related to
fetal abnormalities than did comparison mothers. Such bias would
lead us to underestimate the risk of congenital abnormalities in
newborns of women with HD.
It has been suggested that mutagenic exposure of germ cells
(that is, chemotherapy or radiation) may decrease the proportion
of male newborns in female survivors of cancer due to sex-linked
lethal mutations (Nagarajan and Robison, 2005). Our data,
Table 3 Congenital abnormalities diagnosed during the first year of life in children of Hodgkin’s disease patients
Congenital abnormalities (CAs)
according to organ system Children
Type of congenital abnormality
according to ICD-8/ICD-10
Group 1 (N¼11) (N¼13)
CA in cardiovascular organs Child 1 Defectus septi atriorum cordis (Q21.1)
CA in respiratory organs Child 2 CA in larynx (not specified) (Q31.8)
CA in urologic organs Child 3 Polycystic, dysplastic kidney (Q61.4)
CA in bones and muscles
Foot Child 4 Pes planus congenitus (Q66.5)
Head, spine, and chest Child 5 (first CA) Pectus excavatum (Q67.6)
Other CA in bones and muscles Child 6 Torticollis congenita (756.81)
Other CA in limbs Child 7, 8, and 9 CA in limb (not specified) (Q74.9) (755.99)
Other CA in bones of skull and face Child 10 CA in bone of skull and face (not specified) (Q75.9)
CA in muscle and bones, Child 5 (second CA) Hernia diaphragmatica congenita (Q79.0)
Not otherwise classified Child 11 (first CA) CA in muscle and bone (not specified) (Q79.8)
Other CA Child 11 (second CA) CA (not specified) (Q89.9)
Group 2 (N¼1) (N¼2)
CA in cardiovascular organs Child 1 (first CA) Defectus septi atriorum cordis (Q21.1)
Chromosomal abnormality Child 1 (second CA) Down’s syndrome (Q90.9)
Group 3 (N¼4) (N¼11)
CA in cardiovascular organs Child 1 (first CA) Tetralogia Steno-Fallot (74.629)
Child 1 (second CA) CA in heart (not specified) (74.699)
Child 2 (first CA) Tetralogia Steno-Fallot (74.629)
Child 2 (second CA) CA in heart (not specified) (74.699)
Child 3 (first CA) Defectus congenitus septi ventricolorum (74.639)
Child 3 (second CA) Defectus congenitus septi atriorum (74.641)
Child 3 (third CA) Other specified CA in heart (74.689)
Child 3 (fourth CA) Coarctatio aortae (74.719)
Child 3 (fifth CA) Transpositio vasorum (74.619)
CA in bones and muscles foot Child 1 (third CA) Pes equino-varus (75.400)
Child 4 Pes calcaneo-valgus (75.402)
Group 1: birth outcome in women diagnosed with Hodgkin’s disease before pregnancy. Group 2: birth outcome in women diagnosed with Hodgkin’s disease during pregnancy.
Group 3: birth outcome in women diagnosed with Hodgkin’s disease within 2 years postpartum.
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newborns in group 1, indicating that earlier treatment for HD is
not a risk factor for early male abortion. For newborns in group 2,
there was an increase in the male proportion compared with
newborns of comparison mothers. This finding is surprising and
may be due to chance. The male proportion of newborns in
Denmark is approximately 51.2% (Hansen et al, 1999).
We believe that our study is the first to estimate relative risks for
congenital abnormalities among newborns of women with HD.
The increased risk estimates found after diagnoses during or
shortly after pregnancy were imprecise. However, it is relevant that
teratogens increase the rate of specific abnormalities but not all
abnormalities (Mitchell, 2000), and we were unable to evaluate the
risk of specific abnormalities. Small cohort studies can detect only
large increases in the risk of specific congenital abnormalities and
are limited in their ability to provide an assurance of safety. Our
finding of a higher risk of abnormalities for newborns of women
with HD from 1991 to 2000 (before their pregnancy) may be a
diagnostic bias caused by a recently increased interest in such risk
after maternal cancer treatment.
Overall, our findings are in line with the existing studies. Two
cohort studies found no substantial increased risk of low birth
weight and no congenital abnormalities among newborns of 15
women with previous HD (Janov et al, 1992) and no increased risk
of preterm birth, low birth weight, stillbirth, congenital abnorm-
alities, or chromosomal abnormalities among 49 children of 16
women and 11 men who had previously been treated for HD
(Swerdlow et al, 1996). Both studies were compared with birth
outcomes in the general population. Another cohort study compared
52 births of 29 women previously treated for HD with births of
siblings of the women (Holmes and Holmes, 1978). There was no
overall increased risk of adverse birth outcome (that is, congenital
abnormalities and stillbirths combined) for HD patients and no
increased risk associated with radiation treatment alone (supra- or
infradiaphragmatic), whereas women treated with both chemotherapy
and radiation were more likely to have an adverse birth outcome
(P¼0.047). These three studies, however, were all based on small
study population and did not control for potential confounders.
Recently, a large cohort study of female survivors of childhood
cancer found that 19.2% of 337 women with childhood HD had
a preterm birth compared with 12.6% among sibling controls
(Signorello et al, 2006). Another study reported 11 stillbirths among
729 births of female survivors of childhood HD, corresponding to a
relative risk of 1.6 (95% CI: 0.64–4.03) (Green et al,2 0 0 2 ) .W ef o u n d
no increased risk of preterm birth and only 1 stillbirth among 192
women, of whom more than 75% had been diagnosed with HD in
adulthood (X20 years of age at diagnosis).
The 26-fold increased risk of a preterm delivery for women
diagnosed with HD during pregnancy reflected a higher rate of
elective early delivery, probably to allow an early start of cancer
therapy. This finding is consistent with another study on pregnant
women with HD (Smith et al, 2001) which identified 172 cases of
HD diagnosed from 9 months preceding delivery until 12 months
after delivery and found relative risks of 2.4 (95% CI: 1.6–3.5) for
prematurity and 3.6 (95% CI: 1.5–8.9) for very low birth weight.
The authors suggested that these findings reflected a higher rate of
elective early deliveries to allow initiation of therapy. In contrast, a
historical cohort study, which included 40 births of women who
were pregnant between 9 months before and 3 months after their
first treatment for HD, reported no increased risk of preterm birth
or induced deliveries (Lishner et al, 1992). Furthermore, it
indicated no difference in mean birth weight compared with
controls and no increased risk of stillbirths, and overall, its
findings corroborate our data, except for preterm births.
The overall findings of this nationwide cohort study are
reassuring, but we cannot rule out the possibility of an increased
risk of congenital abnormalities in offspring of women diagnosed
with HD before pregnancy.
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